{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:20:47Z","timestamp":1779888047947,"version":"3.53.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment of chronic myeloid leukaemia (CML) is based on tyrosine kinase inhibitors (TKI), whose introduction in 2001 improved the survival rate after 5\u00a0years from 40 to 90%. The longevity increase has been accompanied by a higher incidence of cardiovascular events (CVE) that can be explained due to the sum of cardiovascular risk factors (CVRF) together with the secondary effects of the TKI. The effect of the TKI over the blood pressure control is still unknown. An observational cross-sectional study of patients with CML under treatment with TKI (imatinib, dasatinib and nilotinib) was conducted. Blood pressure was analyzed through sphygmomanometer and 24-h ambulatory blood pressure monitoring (ABPM). A total of 73 patients were included, 57 treated with a single line of treatment. 32.9% of the total of individuals under this study showed uncontrolled blood pressure according to the ABPM. The factors related to uncontrolled BP were overweight, dyslipidemia, alcohol use, pulse wave velocity a high\/very high cardiovascular risk. The subjects who received treatment with nilotinib did present worse control of their blood pressure in ABPM than those treated with imatinib and dasatinib (p\u2009=\u20090.041). This finding could indicate that an uncontrolled blood pressure is implied in the pro-inflammatory and pro-atherogenic mechanism underlying the development of the cardiovascular disease in those patients under treatment with nilotinib. The ABPM is a useful tool in the diagnosis and treatment of HT, being the reason why it should be included in the assessment of patients with CML whose HT diagnosis proves uncertain.\n<\/jats:p>","DOI":"10.1038\/s41598-021-94127-2","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T10:03:18Z","timestamp":1626688998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Arterial hypertension assessment in a population with chronic myeloid leukemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Ricardo","family":"Roa-Chamorro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ja\u00e9n-\u00c1guila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Puerta-Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Torres-Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Gonz\u00e1lez-Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Mediavilla-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"94127_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).","journal-title":"N. Engl. J. Med."},{"key":"94127_CR2","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"94127_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson, R. A. et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26, 2197\u20132203 (2012).","journal-title":"Leukemia"},{"key":"94127_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour, E. et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123, 494\u2013500 (2014).","journal-title":"Blood"},{"key":"94127_CR5","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes, J. E. et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J. Clin. Oncol. 30, 3486\u20133492 (2012).","journal-title":"J. Clin. Oncol."},{"key":"94127_CR6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes, J. E. et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367, 2075\u20132088 (2012).","journal-title":"N. Engl. J. Med."},{"key":"94127_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent, P. et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk. Res. 59, 47\u201354 (2017).","journal-title":"Leuk. Res."},{"issue":"6","key":"94127_CR8","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim, T. D. et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27(6), 1316\u20131321 (2013).","journal-title":"Leukemia"},{"key":"94127_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes, J. E. et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial. Blood 132, 393 (2018).","journal-title":"Blood"},{"issue":"35","key":"94127_CR10","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J. & Deininger, M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol. 33(35), 4210\u20134218 (2015).","journal-title":"J. Clin. Oncol."},{"key":"94127_CR11","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","volume":"42","author":"RM Shallis","year":"2020","unstructured":"Shallis, R. M. et al. Epidemiology of the classical myeloproliferative neoplasms. The four corners of an expansive and complex map. Blood Rev. 42, 100706 (2020).","journal-title":"Blood Rev."},{"issue":"7","key":"94127_CR12","doi-asserted-by":"publisher","first-page":"E159","DOI":"10.1002\/ajh.25102","volume":"93","author":"G Caocci","year":"2018","unstructured":"Caocci, G. et al. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. Am. J. Hematol. 93(7), E159\u2013E161 (2018).","journal-title":"Am. J. Hematol."},{"issue":"3","key":"94127_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","volume":"94","author":"M Breccia","year":"2015","unstructured":"Breccia, M., Molica, M., Zacheo, I., Serrao, A. & Alimena, G. Application of systematic coronary risk evaluation chart to identify chronic myeloid. Ann. Hematol. 94(3), 393\u2013397 (2015).","journal-title":"Ann. Hematol."},{"key":"94127_CR14","unstructured":"National Comprehensive Cancer Network. Chronic myeloid leukemia. V.1. 2017, Fort Washington, PA. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf (Accessed 4 January 2017)."},{"key":"94127_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2016.70.2944","volume":"5","author":"J Cortes","year":"2017","unstructured":"Cortes, J. & Hochhaus, A. How does one decide which tyrosine kinase inhibitor to use for the initial treatment of chronic-phase chronic myeloid leukemia?. J. Clin. Oncol. 5, 567\u2013568 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"94127_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/1078155212457968","volume":"19","author":"A Sevin","year":"2013","unstructured":"Sevin, A., Chen, A. & Atkinson, B. Tyrosine Kinase Inhibitor-Induced Hypertension. J. Oncol. Pharm. Pract. 19(3), 257\u2013260 (2013).","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"10","key":"94127_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.clml.2017.06.011","volume":"17","author":"AD Coutinho","year":"2017","unstructured":"Coutinho, A. D., Makenbaeva, D., Farrelly, E., Landsman-Blumberg, P. B. & Lenihan, D. Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States. Clin. Lymphoma Myeloma Leuk. 17(10), 676\u2013683 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"94127_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MBP.0b013e328348b688","volume":"16","author":"H Takahashi","year":"2011","unstructured":"Takahashi, H., Yoshika, M. & Yokoi, T. Validation of home blood pressure-monitoring devices, Omron HEM-1020 and Omron i\u2013Q132 (HEM-1010-E), according to the European Society of Hypertension International Protocol. Blood Press. Monit. 16(4), 203\u2013207 (2011).","journal-title":"Blood Press. Monit."},{"issue":"2","key":"94127_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.HYP.20.2.227","volume":"20","author":"A Groppelli","year":"1992","unstructured":"Groppelli, A., Omboni, S., Parati, G. & Mancia, G. Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-arterial blood pressure. Hypertension 20(2), 227\u2013232 (1992).","journal-title":"Hypertension"},{"issue":"33","key":"94127_CR20","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018\u00a0ESC\/ESH\u00a0guidelines\u00a0for the management of arterial\u00a0hypertension. Eur. Heart J. 39(33), 3021\u20133104 (2018).","journal-title":"Eur. Heart J."},{"issue":"7","key":"94127_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/hr.2011.53","volume":"34","author":"A Kollias","year":"2011","unstructured":"Kollias, A., Xilomenos, A., Protogerou, A., Dimakakos, E. & Stergiou, G. S. Automated determination of the ankle-brachial index using an oscillometric blood pressure monitor: Validation vs. Doppler measurement and cardiovascular risk factor profile. Hypertens. Res. 34(7), 825\u2013830 (2011).","journal-title":"Hypertens. Res."},{"issue":"3","key":"94127_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MBP.0b013e328353ff63","volume":"17","author":"W Weiss","year":"2012","unstructured":"Weiss, W. et al. Oscillometric estimation of central blood pressure: Validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press. Monit. 17(3), 128\u2013131 (2012).","journal-title":"Blood Press. Monit."},{"key":"94127_CR23","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1136\/bmj.304.6836.1196","volume":"304","author":"PH Winocour","year":"1992","unstructured":"Winocour, P. H. Microalbuminuria. Br. Med. J. 304, 1196\u20131197 (1992).","journal-title":"Br. Med. J."},{"key":"94127_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0002-8703(49)90562-1","volume":"37","author":"M Sokolow","year":"1949","unstructured":"Sokolow, M. & Lyon, T. Ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart J. 37, 161\u2013186 (1949).","journal-title":"Am. Heart J."},{"key":"94127_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/01.CIR.75.3.565","volume":"75","author":"PN Casale","year":"1987","unstructured":"Casale, P. N., Devereux, R. B., Alonso, D. R., Campo, E. & Kligfield, P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: Validation with autopsy findings. Circulation 75, 565\u2013572 (1987).","journal-title":"Circulation"},{"issue":"5","key":"94127_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton, J. H. et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international: An international, randomised, open-label, phase 3 trial. Lancet Oncol. 17(5), 612\u2013621 (2016).","journal-title":"Lancet Oncol."},{"key":"94127_CR27","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang, X., Cortes, J. & Kantarjian, H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118, 3123\u20133127 (2012).","journal-title":"Cancer"},{"key":"94127_CR28","doi-asserted-by":"publisher","first-page":"e92146","DOI":"10.1371\/journal.pone.0092146","volume":"9","author":"JC Uitdehaag","year":"2014","unstructured":"Uitdehaag, J. C. et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE 9, e92146 (2014).","journal-title":"PLoS ONE"},{"key":"94127_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531\u20132541 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"94127_CR30","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani, D. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17), 2128\u20132137 (2012).","journal-title":"Circulation"},{"issue":"17","key":"94127_CR31","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2169\/internalmedicine.51.7472","volume":"51","author":"M Sano","year":"2012","unstructured":"Sano, M. et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia\u2014Critical alert. Intern. Med. 51(17), 2337\u20132340 (2012).","journal-title":"Intern. Med."},{"issue":"6","key":"94127_CR32","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha, C., Lam, W. & Hillis, C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A meta-analysis. Leuk. Lymphoma 57(6), 1300\u20131310 (2016).","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"94127_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/leu.2013.320","volume":"28","author":"K Mayer","year":"2014","unstructured":"Mayer, K., Gielen, G. H., Willinek, W., M\u00fcller, M. C. & Wolf, D. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib. Leukemia 28(4), 976\u2013977 (2014).","journal-title":"Leukemia"},{"key":"94127_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.recesp.2015.11.036","volume":"69","author":"E Men\u00e9ndez","year":"2016","unstructured":"Men\u00e9ndez, E. et al. Prevalencia, diagn\u00f3stico, tratamiento y control de la hipertensi\u00f3n arterial en Espa\u00f1a. Resultados del estudio Diabetes. Rev. Esp. Cardiol. 69, 572\u2013578 (2016).","journal-title":"Rev. Esp. Cardiol."},{"issue":"1","key":"94127_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","volume":"55","author":"F Soriguer","year":"2012","unstructured":"Soriguer, F. et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Diabetes Study. Diabetolog\u00eda 55(1), 88\u201393 (2012).","journal-title":"Diabetolog\u00eda"},{"key":"94127_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.recesp.2012.02.005","volume":"65","author":"P Guallar-Castillon","year":"2012","unstructured":"Guallar-Castillon, P. et al. Magnitud y manejo de la hipercolesterolemia en la poblaci\u00f3n adulta de Espa\u00f1a, 2008\u20132010: el estudio ENRICA. Rev. Esp. Cardiol. 65, 551\u2013558 (2012).","journal-title":"Rev. Esp. Cardiol."},{"issue":"6","key":"94127_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.recesp.2016.02.010","volume":"69","author":"J Aranceta-Bartrina","year":"2016","unstructured":"Aranceta-Bartrina, J., P\u00e9rez Rodrigo, C., Alberdi-Aresti, G., Ramos-Carrera, N. & L\u00e1zaro-Masedo, S. Prevalence of general obesity and abdominal obesity in the Spanish adult population (aged 25\u201364 years) 2014\u20132015: The ENPE study. Rev. Esp. Cardiol. (Engl. Ed.) 69(6), 579\u2013587 (2016).","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"94127_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.recesp.2010.10.010","volume":"64","author":"F L\u00f3pez-Jim\u00e9nez","year":"2011","unstructured":"L\u00f3pez-Jim\u00e9nez, F. & Cort\u00e9s-Bergoderi, M. Obesidad y coraz\u00f3n. Rev. Esp. Cardiol. 64, 140\u2013149 (2011).","journal-title":"Rev. Esp. Cardiol."},{"key":"94127_CR39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/HJR.0b013e3282f37a45","volume":"15","author":"G Journath","year":"2008","unstructured":"Journath, G., Hell\u00e8nius, M. L., Petersson, U., Theobald, H. & Nilsson, P. M. Sex differences in risk factor control of treated hypertensives: A national primary healthcare-based study in Sweden. Eur. J. Cardiovasc. Prev. Rehabil. 15, 258\u2013262 (2008).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"94127_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1157\/13108996","volume":"60","author":"GC Rodr\u00edguez-Roca","year":"2007","unstructured":"Rodr\u00edguez-Roca, G. C. et al. Caracter\u00edsticas de la presi\u00f3n arterial en una poblaci\u00f3n dislip\u00e9mica espa\u00f1ola asistida en atenci\u00f3n primaria. Estudio LIPICAPPA. Rev. Esp. Cardiol. 60, 825\u2013832 (2007).","journal-title":"Estudio LIPICAPPA. Rev. Esp. Cardiol."},{"issue":"5","key":"94127_CR41","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5), 1044\u20131054 (2016).","journal-title":"Leukemia"},{"issue":"12","key":"94127_CR42","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","volume":"17","author":"N Aghel","year":"2017","unstructured":"Aghel, N., Lipton, J. H., Atenafu, E. G., Kim, D. D. H. & Delgado, D. H. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: Long-term follow-up. Clin. Lymphoma Myeloma Leuk. 17(12), 870\u2013878 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"44","key":"94127_CR43","doi-asserted-by":"publisher","first-page":"72311","DOI":"10.18632\/oncotarget.11100","volume":"7","author":"M Bocchia","year":"2016","unstructured":"Bocchia, M. et al. Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget 7(44), 72311\u201372321 (2016).","journal-title":"Oncotarget"},{"issue":"1","key":"94127_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11899-020-00560-x","volume":"15","author":"D Gustafson","year":"2020","unstructured":"Gustafson, D., Fish, J. E., Lipton, J. G. & Angel, N. Mechanism of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr. Hematol. Malig. Rep. 15(1), 20\u201330 (2020).","journal-title":"Curr. Hematol. Malig. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94127-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:30:41Z","timestamp":1670067041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94127-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94127"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94127-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14637"}}